Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.
Investigators from the TRANSITION-T2D study join Diabetes Dialogue to discuss the study and implications for care.
W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics
Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.
Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.
At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.
At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.
In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.
In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.
As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
In this episode of MEDcast, Dr Julia Blanchette joins Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, discuss strategies to empower young adults with the skills and resources necessary to effectively manage type 1 diabetes and maintain a healthy lifestyle.
Diabetes care experts discuss practical strategies to help young adults with type 1 diabetes transition from pediatric to adult endocrinology care, and how families can support them during this transition.
In this episode, hosts sit down for an in-depth discussion of the 11 person-centered algorithms for clinical decision-making featured in the AACE's 2023 Comprehensive Type 2 Diabetes Management Algorithm.
Dr Julia Blanchette explains how a micro video toolkit developed by her team can help young adults alleviate the financial stress of type 1 diabetes.
Julia Blanchette, PhD, RN; Natalie Bellini, DNP, FNP-BC; and Diana Isaacs, PharmD, BC-ADM, CDCES discuss the challenges young adults with type 1 diabetes encounter, including managing their healthcare finances.
Dr Julia Blanchette highlights some of the latest advancements in automated insulin delivery systems that can aid in the self-management of type 1 diabetes.
In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.
In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
On this episode of MEDcast, Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC are joined by Dr George Bakris to discuss the latest advances in treatments and comprehensive care for patients with diabetes and chronic kidney disease.
Drs Diana Isaacs and Natalie Bellini emphasize the need for early detection of diabetic kidney disease through the monitoring of cardiometabolic risk factors.
George Bakris, MD, shares best practices for co-management and providing comprehensive care for patients with diabetic kidney disease.
Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Dr George Bakris elaborates on the risk factors, monitoring, treatment objectives, and the impact of diet and exercise in preventing the progression of diabetic kidney disease.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
Fran Cogen, MD, joins Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, on this MEDcast episode to stress the significance of early detection for type 1 diabetes. The conversation covers screening protocols and options, as well as emerging treatments that can delay the onset of the disease.
Drs Diana Isaacs and Natalie Bellini summarize the key takeaways on screening for pediatric and adult-onset type 1 diabetes and strategies to improve screening.
An expert pediatric endocrinologist discusses best practices for referring patients to a specialist in type 1 diabetes, as well as the potential of new therapies in delaying the progression of the disease.
Dr Fran Cogen discusses the screening of autoantibodies for type 1 diabetes and provides insights on how to interpret the results of the screening tests.
